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Abstract: According to a recent consensus, cachexia is a complex metabolic syndrome 
associated with underlying illness and characterized by loss of muscle with or without loss 
of fat mass. The prominent clinical feature of cachexia is weight loss. Cachexia occurs in the 
majority of cancer patients before death and it is responsible for the deaths of 22% of cancer 
patients. Although bodyweight is the most important endpoint of any cachexia treatment, body 
composition, physical performance and quality of life should be monitored. From the results 
presented here, one can speculate that a single therapy may not be completely successful in the 
treatment of cachexia. From this point of view, treatments involving different combinations are 
more likely to be successful. The objectives of any therapeutic combination are two-fold: an 
anticatabolic aim directed towards both fat and muscle catabolism and an anabolic objective 
leading to the synthesis of macromolecules such as contractile proteins.
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Introduction
A definition of cachexia
Perhaps the most common manifestation of severe disease, such as acquired 
immunodeficiency syndrome (AIDS), chronic heart failure (CHF) and cancer, is the 
development of cachexia. Although there is no single, generally agreed upon, defi-
nition of cachexia, a recent consensus states that “cachexia is a complex metabolic 
syndrome associated with underlying illness and characterized by loss of muscle 
with or without loss of fat mass. The prominent clinical feature of cachexia is weight 
loss in adults (corrected for fluid retention) or growth failure in children (excluding 
endocrine disorders). Anorexia, inflammation, insulin resistance and increased muscle 
protein breakdown are frequently associated with cachexia”. Cachexia is distinct from 
starvation, age-related loss of muscle mass, primary depression, malabsorption and 
hyperthyroidism and is associated with increased morbidity.1 Cachexia occurs in the 
majority of cancer patients before death and, according to Warren, it is responsible for 
the deaths of 22% of cancer patients.2 Interestingly, in studies performed before the era 
of highly active antiretroviral therapy, estimates of prevalence of wasting as the first 
AIDS-defining diagnosis ranged up to 31%.3 Fatigue, as a result of muscle wasting, is 
an extremely common symptom in cardiac cachexia patients. This condition is observed 
among a high percentage of chronic heart failure patients.4 In cancer, cachexia is a 
multi-organ syndrome characterized by weight loss (at least 5%), muscle and adipose 
tissue wasting and inflammation – often associated with anorexia. The abnormalities Cancer Management and Research 2010:2 28
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associated with cachexia include alterations in carbohydrate, 
lipid and protein metabolism.5 These metabolic abnormalities 
are caused by both humoral inflammatory mediators (such 
as cytokines) and of tumor origin.
Although a plethora of treatments for the cachectic 
syndrome have been proposed, unfortunately, not a single 
one is completely satisfactory. When treating weight loss 
associated with cachexia, two targets have to be considered. 
Firstly, food intake should be controlled with the aim of 
reducing anorexia (Figure 1). In addition, contributing factors 
to decreased food intake could be assessed and treated. This 
clearly constitutes the first aim of the therapy of wasting. 
Secondly, providing complete nutritional requirements by 
means of total parenteral nutrition does not abrogate the 
weight loss. It is thus clear that, in addition to controlling 
food intake, the metabolic disturbances associated with 
tumor burden contribute most importantly to the appearance 
of cachexia. Therefore, neutralizing the metabolic alterations 
which include abnormal carbohydrate metabolism, lipid 
mobilization, hepatic protein metabolism and, above all, 
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Figure 1 Therapeutic targets for cancer cachexia. There are different therapeutic approaches to fight anorexia and metabolic disturbances based in the combination of 
nutritional support, nutraceuticals and specific drugs. The objectives for cachexia treatment are two: anticatabolic (directed towards both fat and muscle) and anabolic (leading 
to the synthesis of macromolecules).Cancer Management and Research 2010:2 29
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alterations in the rate of skeletal muscle protein breakdown 
is of paramount importance,6,7 (Figure 1).
There are novel approaches for reaching the targets 
referred to above in addition to nutritional support. The use 
of the nutraceuticals has led to interesting results.8,9 In order 
to reverse metabolic disturbances, many drugs have been 
proposed and used in clinical trials, while others are still 
under investigation using experimental animals. The best 
treatment of the cachectic syndrome is most likely to be a 
multifactorial approach. In relation to this, the combina-
tion of nutritional support with different nutraceuticals has 
already been reported to be relatively successful.10 A combi-
nation of nutritional support and nutraceuticals with specific 
drugs may lead to optimal results. There are two objectives of 
any therapeutic combination: an anti-catabolic aim directed 
towards both fat and muscle catabolism, and an anabolic 
objective leading to the synthesis of macromolecules such 
as contractile proteins (Figure 1).
Assessing endpoints
Independent of the treatment, the monitoring of cachexia is 
a key issue during therapy. Different parameters can be used 
but, inevitably, they rely on the targets mentioned before. 
In relation to anorexia, food intake, intestinal absorption, 
delayed gastric emptying, and dysphagia constitute impor-
tant parameters to be monitored. Often, the treatment of the 
tumor also causes alterations in both the taste and smell of 
foods; therefore, this should also be taken into consideration. 
In addition, metabolic alterations are varied and complex. 
Assessment of energy expenditure (both resting and total), 
inflammation (C-reactive protein), glucose intolerance, fat 
mobilization (lipolysis) and protein breakdown are important 
endpoints and should ideally be monitored, (Figure 2).
Although bodyweight is the most important endpoint 
of any cachexia treatment, body composition (lean body 
mass, fat mass, water) should be analyzed by means of 
BIA (body impedance analysis), DEXA (dual-energy X-ray 
absorptiometry) or CT-scanning (computer tomography), 
since an increase in bodyweight based on fat or water – without 
an increase in lean body mass – may not be relevant (Figure 2). 
It is also important to also include measurements of physical 
performance (eg, the monitoring of total activity and grip 
force evaluation). Indeed, physical performance is linked 
with quality of life (that can be estimated through the use of 
different questionnaires), one of the most important endpoints 
of any cachexia therapy. Finally in relation to cancer treat-
ments, survival is an endpoint that reflects the impact of any 
cachexia therapy11 (Figure 2).
Approaches to the treatment 
of cachexia
Several pharmacological and nutritional approaches have 
been used (Table 1). Bearing in mind that both anorexia and 
metabolic disturbances are involved, the development of 
different therapeutic strategies has focused on the following 
two factors.
improving appetite
Progesterone derivates
Megestrol acetate and medroxyprogesterone are synthetic, 
orally active derivatives of the naturally occurring hormone 
progesterone. In humans these compounds have been found 
to improve appetite, caloric intake and nutritional status in 
several clinical trials.12–14 The human trials involving proges-
terone derivatives have on the whole demonstrated, with few 
exceptions, a favorable effect on appetite and weight gain, 
which is a positive value for body image. However, this has 
been mainly attributed to an increased fat mass, not to muscle 
mass.15 Oral suspension of the progestational agent may be 
particularly useful in patients with advanced disease, where 
taking larger amounts of pills may lead to the decrease of 
patient compliance. Recent data by Tomíska et al showed that 
an oral megestrol acetate suspension given to patients with 
advanced cancer and additionally suffering from anorexia 
resulted in an improvement of appetite and quality of life.16 
A recent meta-analysis concludes that megestrol acetate is 
able to reduce the symptoms of cachexia with no effect on 
survival or quality of life.17
Cannabinoids
Cannabinoids, which are present in marijuana, have a defini-
tive effect on weight gain and have been used to increase 
food intake in cancer patients. The mechanism by which 
cannabinoids exert their effects has yet to be clarified. It was 
postulated that they may act via endorphin receptors, or by 
inhibiting prostaglandin synthesis.18 Other reports suggest 
that the marijuana derivative may act by inhibiting cytokine 
production and/or secretion.19,20 A recent clinical trial, however, 
has shown very little efficacy of either orally administered 
cannabinoid extract or ∆9-tetrahydrocannabinol in treating 
patients with cancer-related anorexia–cachexia syndrome.21
Cyproheptadine
Considerable evidence, both in humans and experimental 
animals, suggests that anorexia may be mediated by an 
increased serotonergic activity in the brain.22 Taking this into 
consideration, attempts to block serotonin activity during Cancer Management and Research 2010:2 30
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cancer cachexia have involved the use of cyproheptadine, 
a serotonin antagonist with antihistaminic properties, usually 
used for the treatment of allergies. Although initial clinical 
data suggested that it had appetite and weight-enhancing 
effects in both patients with cancer-related cachexia and 
without; however, it did not prevent progressive weight loss 
in patients with advanced malignant disease.23 A recent pilot 
study, however, demonstrates that cyproheptadine treatment 
was able to enhance bodyweight in children with cachexia.24 
Future clinical trials with other anti-serotonergic drugs are 
necessary to define the role of the serotonergic system in 
the development of cancer cachexia.
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Figure 2 Cachexia endpoints. The monitoring of cachexia is a key issue during therapy. Different parameters in relation with anorexia and metabolic disturbances should be 
taken into consideration. Although bodyweight is the most important endpoint, body composition, physical performance and survival, which reflect the impact of the treatment, 
should also be taken into consideration and analyzed.
Abbreviation: QoL, quality of life.Cancer Management and Research 2010:2 31
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Corticosteroids
This group of hormones was one of the first pharmaco-
logical approaches for the treatment of cancer related 
anorexia. Indeed, they have been used to increase food 
intake in cancer patients and a number of uncontrolled 
studies have shown that some of the symptoms in cancer 
patients (such as anorexia and asthenia) can be partially 
mitigated by corticosteroids treatment, giving the patient 
an increased sensation of well being. Dexamethasone sig-
nificantly decreases appetite loss and weight loss in lung 
cancer patients treated with chemotherapy, although it has 
little influence on appetite improvement and weight gain.25 
Although corticosteroid treatment has been associated with 
low toxicity in several trials, prolonged treatment seems to 
lead to weakness, delirium, osteoporosis and immunosup-
pression, all of which are commonly present in advanced 
cancer patients.26
However, corticosteroids do seem to improve the quality 
of life of terminal cancer patients and can be used as palliative 
therapy. Unfortunately, corticosteroid treatment does not 
seem to have any significant effects in the reduction of 
mortality.27
Orexigenic and anorexigenic mediators: ghrelin
The orexigenic mediator, ghrelin (GH) – a novel endogenous 
ligand for the growth hormone secretagogue receptor – has 
recently been reported as having a key role in increasing 
appetite and therefore food intake. In addition to increasing 
food intake, the peptide inhibits leptin and proinflammatory 
cytokines expression.28 An experimental study has shown 
that repeated administration of ghrelin improves cardiac 
structure and function, and attenuates the development of 
cardiac cachexia in CHF. These results suggest that ghrelin 
has cardiovascular effects and regulates energy metabolism 
through GH-dependent and GH-independent mechanisms.29 
Therefore the administration of ghrelin may be a new thera-
peutic strategy for the treatment of severe CHF. A phase I 
randomized, placebo-controlled, double-blind, multiple-dose 
study using an oral ghrelin mimetic demonstrated an increase 
of bodyweight in healthy volunteers.30
Melanocortin antagonists
Melanocortin (MC4) receptor is involved in the anorexi-
genic cascade, modulating food intake by two different 
mechanisms which are both leptin-dependent and leptin-
independent.31 The use of MC4 antagonists has proved to 
be effective in preventing anorexia, loss of lean body mass 
and basal energy expenditure in experimental animals 
suffering from cachexia.32,33 However, no data on human 
subjects are available and future clinical trials may prove the 
efficacy of this type of antagonist in the treatment of human 
cachexia.
Neutralizing metabolic disturbances
Cytokines-based therapeutic approaches
Cytokines act on multiple target sites, such as bone marrow, 
myocytes, hepatocytes, adipocytes, endothelial cells and 
neurons, where they produce a complex cascade of bio-
logical responses that lead to the wasting associated with 
cachexia. The cytokines that have been implicated in this 
cachectic response are tumor necrosis factor (TNF)-α, inter-
leukin (IL)-1, IL-6 and interferon-γ (IFN-γ). Interestingly, 
these cytokines share the same metabolic effects, and their 
activities are closely interrelated. In many cases, these cyto-
kines exhibit synergic effects when administered together.34 
Therefore therapeutic strategies have been based on either 
blocking their synthesis or their action.35
Table 1 Efficiency of the different anti-cachexia treatments
Drug  Experimental  
animals
Humans 
Progesterone derivatives ++ ++
Cannabinoids ++ +
Cyproheptadine + +
Corticosteroids – –
Ghrelin ++ ++
Pentoxifylline ++ ?
Thalidomide + +
Anti-cytokine antibodies  
and soluble receptors
+++ –
Anti-inflammatory cytokines ++ ?
Anabolic steroids ++ ++
β2-adrenergic agonists +++ ?
ω-3-fatty acids ++ ++
Prostaglandin inhibitors ++ +
ACe inhibitors ++ ?
ePO ? ++
ATP ? +
Creatine ? +
Amino acids ++ +
Proteasome inhibitors ? ?
Data refer to experimental and clinical trials. +, slight beneficial effect. ++ relatively 
good results. +++, satisfactory treatment. –, unsuccessful trial. ?, unknown. Table 
adapted from   Argilés et al.
Abbreviations: ACe, angiotensin-converting enzyme; ePO, erythropoietin; 
ATP,  adenosine triphosphate.Cancer Management and Research 2010:2 32
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Pentoxifylline
Pentoxifylline, a methylxanthine derivative, is a phosphodi-
esterase inhibitor that inhibits TNF synthesis by decreasing 
gene transcription. This drug was originally used for the 
treatment of various types of vascular insufficiency because 
of its hemorheological activity, thought to be based on its 
ability to reduce blood viscosity and increase the filterability 
of blood cells. Although several studies using animal models 
suggest that pentoxifylline is able to decrease the cytokine 
induced toxicity of antineoplastic agents while preserving 
anti-tumor treatment efficacy.36 Clinical studies have shown 
that the drug failed to improve appetite or increase the weight 
of cachectic patients,37 and patients in the study frequently 
reported gastrointestinal side effects. However, the reported 
clinical trials have been relatively small and therefore larger 
randomized studies are necessary to assess the efficacy of 
pentoxifylline in the treatment of cancer cachexia.
Thalidomide
Thalidomide (α-N-phthalimidoglutaramide) is a drug that 
in the past has been, unfortunately, associated with tragedy. 
Indeed, its use as a sedative in pregnant women caused over 
10,000 cases of severe malformations in newborn children. 
However, a certain revival has improved the drug’s profile, 
since it has been demonstrated to suppress TNF-alpha 
production in monocytes in vitro and to normalize elevated 
TNF-alpha levels in vivo.38,39 A randomized placebo-
controlled trial in patients with cancer cachexia showed 
that the drug was well-tolerated and effective at attenuating 
loss of weight and lean body mass in patients with advanced 
pancreatic cancer, although no improvement in survival was 
obtained.40
Antibodies and soluble receptors
The use of anti-cytokine antibodies (either mono or poly-
clonal) and cytokine receptor antagonists or soluble receptors 
has led to some interesting results. In rats bearing the Yoshida 
AH-130 ascites hepatoma (a highly cachectic tumor) anti-
TNF therapy resulted in a partial reversal of the abnormali-
ties associated with both lipid and protein metabolism.41,42 
In humans however, clinical trials using anti-TNF treatment 
has led to poor results in reversing protein catabolism asso-
ciated with sepsis and cancer cachexia.43 Concerning IL-6, 
experimental models have proved that the use of antibodies 
is highly effective in preventing tumor-induced waste.44 
Strassman et al have demonstrated that the experimental 
drug suramine (which prevents the binding of IL-6 to its cell 
surface receptor, as demonstrated by radioreceptor-binding 
assay and affinity binding experiments) partially blocks 
(up to 60%) the catabolic effects associated with the growth 
of the colon-26 adenocarcinoma in mice.45
Concerning other cytokines, anti-IFN-γ therapy has 
also been effective in reverting cachexia in mice bearing 
the Lewis lung carcinoma, although there is a paucity of 
clinical data.46 Additionally blocking IL-1 actions by means 
of the IL-1 receptor antagonist (IL-1ra) in tumor-bearing rats 
had no effect on either bodyweight or reversal of metabolic 
changes.47 A similar approach is the use of anti-cytokine 
strategies such as etanercept (fusion protein directed against 
p75 TNF receptor). Monk et al showed in a clinical pilot study 
with several advanced malignancies that patients treated with 
etanercept combined with an antitumor agent (docetaxel) had 
less fatigue and improved tolerability of the antitumoral treat-
ment. However, the routine use of anti-cytokine antibodies 
is, at present, too expensive due to the fact that this type of 
therapy requires a very large number of antibody molecules 
in order to block cytokine action completely.48
Anti-inflammatory/anabolic cytokines
The degree of the cachectic syndrome is dependent not 
only on the production of the cytokines known as catabolic 
proinflammatory cytokines, but also on the so-called anti-
inflammatory cytokines, such as IL-4, IL-10, and IL-12. 
Interleukin-15 has been reported to be an anabolic factor for 
skeletal muscle.49 This cytokine is able to decrease protein 
degradation, decrease the rate of DNA fragmentation and 
increase UCP3 expression in skeletal muscle, these being the 
most important trends associated with muscle wasting during 
cancer cachexia.50,51 In vitro experiments carried out using 
both isolated incubated muscle and muscle cells in culture 
corroborate the in vivo observations indicating a direct action 
of the cytokine upon skeletal muscle.52 Although no clini-
cal data are available, treatment of cachectic experimental 
animals with IL-15 leads to an improvement of muscle mass 
and performance.50
Other therapeutic approaches
Anabolic steroids
Although treatment with derivatives of gonadal steroids 
can have significant side effects, such as masculinization, 
fluid retention and hepatic toxicity, they promote protein 
accumulation and could be used to counteract the pro-
gressive nitrogen loss associated with cachexia. Recent 
data from a double-blind placebo-controlled trial suggest 
that nandrolone decanoate is effective in the treatment 
of cachectic AIDS patients, increasing lean body mass, Cancer Management and Research 2010:2 33
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quality of life and decreasing anti-AIDS treatment toxicity.53 
A recent clinical trial using a non-steroidal selective andro-
gen receptor modulator (SARM) carried out to increase lean 
body mass and improve physical performance in healthy 
elderly subjects was successful and the potential activity of 
this class of drugs should be taken into consideration for 
cancer cachexia.54
β2-adrenergic agonists
These molecules are potentially very interesting since they 
have important effects on protein metabolism in skeletal 
muscle, favoring protein deposition. Apart from the older 
β2-adrenergic agonists, such as clenbuterol, the interest has 
been recently focused on newer drugs such as formoterol. 
In particular, the use of this β2-adrenergic agonist in experi-
mental animals has proved to be useful in reversing muscle 
wasting associated with cancer.55 In addition to its relatively 
low toxicity, formoterol is able to reverse the muscle-wasting 
process. The anti-wasting effects of the drug were based on 
both an activation of the rate of protein synthesis and an inhi-
bition of the rate of muscle proteolysis. Northern blot analysis 
revealed that formoterol treatment resulted in a decrease in 
the mRNA content of ubiquitin and proteasome subunits in 
gastrocnemius muscles. This, together with the decreased 
proteasome activity observed, suggested that the main anti-
proteolytic action of the drug may be based on inhibition of 
the ATP-ubiquitin-dependent proteolytic system.55 Interest-
ingly, the β2-agonist was also able to diminish the increased 
rate of muscle apoptosis present in tumor-bearing animals, 
and was able to facilitate muscle regeneration by stimulating 
satellite cells proliferation. The results indicate that formoterol 
exerted a selective, powerfully protective action on heart 
and skeletal muscle by antagonizing the enhanced protein 
degradation that characterizes cancer cachexia. Formoterol 
may potentially be a therapeutic tool in pathological states 
wherein muscle protein hypercatabolism is a crucial feature, 
such as cancer cachexia or other wasting diseases.55
β-blockers
These drugs can reduce body energy expenditure and improve 
efficiency of substrate utilization. Interestingly, patients with 
CHF treated with β-blockers can increase total body fat mass 
and partially reverse cachexia.56
ω-3-fatty acids
ω-3-Polyunsaturated fatty acids (ω-3-PUFA), present in 
large amounts in fish oil, have been proposed to be very 
active in reducing either tumor growth or the associated 
tissue wasting, particularly that of the adipose mass.57,58 
Interest in ω-3-PUFA was originated from the observation 
that populations consuming a diet rich in such constituents 
showed the lowest incidence of certain types of cancer. An 
improvement in the lean body mass and quality of life was 
observed in a randomized double-blind trial using a protein 
and energy dense ω-3-fatty acid-enriched oral supplement, 
provided that its consumption was equal to or in excess of 
2.2 g eicosapentaenoic acid (EPA)/day.59 However, recent 
data arising from a large multicentre double-blind placebo-
controlled trial, indicates that EPA administration alone is 
not successful in the treatment of weight loss in patients 
with advanced gastrointestinal or lung cancer.60 Moreover, 
a recent meta-analysis based on five trials concluded that 
there were insufficient data to establish whether oral EPA 
was better than placebo. Comparisons of EPA combined with 
a protein energy supplementation versus a protein energy 
supplementation without EPA, in the presence of an appetite 
stimulant (Megace®) provided no evidence that EPA improves 
symptoms associated with the cachexia syndrome often seen 
in patients with advanced cancer.61 In CHF, fish oils produce 
anti-inflammatory effects by decreasing TNF-α production 
and improve bodyweight.62 However, recent trials support 
the benefits of fish oil therapy for cachexia. Guarcello and 
colleagues used EPA-enriched oral nutrition in patients with 
lung cancer reported a positive effects on bodyweight and 
quality of life.63 A similar study by Read et al suggests that 
nutrition intervention with EPA improves bodyweight and 
reduces inflammation.64 Similarly, a double-blind randomized 
trial using ω-3-fatty acids in non-small cell lung carcinoma, 
reported increased bodyweight in comparison with the con-
trol subjects receiving standard nutrition supplementation.65 
In children receiving chemotherapy the use of a protein and 
energy dense EPA-containing supplement resulted in an 
improvement of both bodyweight and body mass index.66 
Ryan and colleagues in a double-blind randomized trial, 
used enteral nutrition based EPA in patients with esophageal 
cancer surgery; the results demonstrated beneficial effects 
on bodyweight.67 Finally, the combination of ω-3-fatty acids 
with the Cox-2 inhibitor celecoxib reduced inflammation and 
increased muscle strength in cachectic cancer patients.68
Amino acids
Peripheral muscle proteolysis, as occurs in cancer cachexia, 
serves to mobilize amino acids required for the synthesis 
of liver and tumor protein.69 Therefore, the administration 
of exogenous amino acids may theoretically serve as a 
protein-sparing metabolic fuel by providing substrates for Cancer Management and Research 2010:2 34
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both muscle metabolism and gluconeogenesis. Therefore 
branched-chain amino acids ([BCAA] such as leucine, iso-
leucine and valine) have been used in parenteral nutrition 
with the aim of improving nitrogen balance and particularly, 
muscle protein metabolism. Tayek and colleagues in a 
prospective, randomized, crossover trial involving patients 
with advanced intra-abdominal adenocarcinoma, concluded 
that BCAA-enriched total parenteral nutrition resulted in 
improved protein accretion and albumin synthesis.70 Simi-
larly, studies with tumor-bearing animals show that high 
BCAA concentrations in total parenteral nutrition have 
beneficial effects on host protein metabolism.71 Cangiano 
et al have proposed that BCAA administration would also 
serve to counteract the anorexia associated with tumor 
growth.72 The authors postulated that increased hypothalamic 
serotonergic activity is one of the pathogenic mechanisms 
leading to the development of cancer anorexia. In addition, 
data from the authors’ own laboratory show that BCAAs 
(in particular leucine) act by decreasing skeletal muscle 
protein degradation, mainly by inhibiting the activation 
of the ubiquitin proteolytic system.73 Free tryptophan (the 
precursor of brain serotonin) is increased during cancer and 
BCAA may act by competing for the same transport system 
as tryptophan across the blood–brain barrier.74,75 This hypoth-
esis has been tested in anorectic cancer patients receiving an 
oral supplementation of BCAA with encouraging results, as 
the treatment decreased the severity of the anorexia in the 
treated patients.73
Glutamine-enriched solutions have also been used in total 
parenteral nutrition with the aim of enhancing immunoregu-
lation of tumor growth, and compensating for the uptake of 
the amino acid by the tumor.76 Indeed, tumor cells are major 
glutamine consumers (for both protein synthesis and oxida-
tion) and, therefore, lead to host glutamine depletion,77,78 
which results in a decreased host immune response and 
gastrointestinal mucosal integrity.76 In patients undergoing 
bone marrow transplantation for hematological malignan-
cies, glutamine supplementation was found to be beneficial, 
improving nitrogen balance and diminishing the incidence 
of clinical infection as compared with the standard paren-
teral nutrition therapy.79 It could be argued that glutamine 
supplementation may facilitate tumor growth as it is one of 
the preferred substrates for fast-growing tumors. However, 
evidence obtained in experimental models demonstrates 
that glutamine supplementation improves the tumoricidal 
effectiveness of methotrexate while reducing its toxicity.80 
As Laviano and colleagues suggest, this could be due to 
the increased number of glutamine-induced tumor cells in 
the S-phase of the cell cycle, during which they are more 
susceptible to chemotherapy.81 The combination of gluta-
mine, arginine and β-hydroxy-β-methylbutyrate – a leucine 
metabolite – has been proven to be effective in increasing 
free fatty mass in advanced cancer patients.82
Increasing evidence suggests that an abnormal cysteine 
and glutathione metabolism plays a decisive role in the 
development of catabolic conditions and associated immu-
nological dysfunctions.83 Indeed, the increased glycolytic 
activity and lactate production that takes place during 
cancer causes an acidification of the muscle cells that 
may result in a decreased transport of glutamate and, in 
an impaired glutathione metabolism.6,83 The acidification 
is aggravated by the fact that the temporary increase of 
intracellular pyruvate causes an increased rate of cysteine/
pyruvate transaminase and, consequently, an increased 
cysteine degradation into sulfate and protons.83 Increased 
intracellular sulfate levels have indeed been found in skel-
etal muscle of tumor-bearing mice.84 This was associated 
with a decrease of the glutathione level in the skeletal 
muscle tissue, thus indicating that the cysteine catabolism 
was increased at the expense of glutathione biosynthesis 
at this time.83 With this in mind, Dröge and colleagues 
suggest that N-acetylcysteine can be used to increase the 
availability of cysteine in the treatment of catabolic states 
such as cancer cachexia.83
Prostaglandin and nitric oxide inhibitors
The effects of prostaglandins on cell growth have been 
studied both in vitro and in vivo,85,86 and it has been proposed 
that cell growth may be controlled by the interconversion 
of different types of prostaglandins. Indeed, large amounts 
of these compounds are found both in tumor tissue and 
plasma from cancer patients.87 Taking this into consideration, 
several studies have examined the role of cyclooxygenase 
(Cox) inhibitors on tumor growth and cachexia. The results 
obtained are clearly contradictory. Whereas Homem-de-
Bittencourt et al reported that indomethacin, ibuprofen 
and aspirin markedly inhibit tumor growth and reduce 
anorexia in rats bearing the Walker-256 carcinosarcoma,88 
McCarthy and Daun (using the same rat tumor model) also 
reported a decrease in tumor weight, but this was not associ-
ated with a reduction of anorexia or loss in bodyweight.89 
Hussey and Tisdale have studied the effects of the Cox-2 
inhibitor meloxican on tumor growth and cachexia in 
the murine adenocarcinoma MAC16. The results suggest 
that the inhibitor is able to effectively attenuate cachexia, 
possibly by exercising a direct effect on skeletal muscle Cancer Management and Research 2010:2 35
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protein degradation.90 Results from a recent pilot study using 
celecoxib in cancer also showed that the Cox-2 inhibitors 
improved weight and quality of life scores.91
Inhibition of nitric oxide production by specific blockade 
of the synthase (NOS) resulted in decreased muscle wasting 
in a model of cachexia. Interestingly, the decrease in body-
weight, the muscle wasting and skeletal muscle molecular 
abnormalities were prevented by the use of both N-nitro-
L-arginine (a NOS inhibitor) and antioxidants.92 Further 
studies with other tumor models are needed before any 
serious conclusions can be drawn about the beneficial effects 
of prostaglandin inhibitors on cancer cachexia.
Angiotensin-converting enzyme inhibitors
In CHF, inhibition of the angiotensin-converting enzyme 
(ACE) by administration of enalapril reduces the risk of 
weight loss and it is linked to improved survival.93 Preliminary 
results demonstrate increased subcutaneous fat (increased 
skin fold thickness) and greater muscle bulk (increased 
mid-upper arm and tight circumferences), together with a 
significant elevation in plasma albumin and hematocrit.94 
ACE inhibitors, like captopril, seem to act by decreasing 
the production of TNF-α by mononuclear cells, suggest-
ing a mechanism that accounts for the beneficial effects 
(related to bodyweight) observed in heart failure patients.95 
The highly lipophilic ACE inhibitor imidapril attenuated 
the development of weight loss in mice bearing the MAC16 
tumor, suggesting that angiotensin II may play a role in the 
development of cachexia in this model.96
Anti-anemic drugs
The administration of erythropoietin (EPO) to cancer patients 
results in a clinical benefit in patients with normal or sub-
normal hemoglobin levels.97 Interestingly Kanzaki and 
colleagues have shown that in tumor-bearing mice the posi-
tive therapeutic effects of EPO in cancer cachexia are due not 
only to improved metabolic and exercise capacity – via an 
increased erythrocyte count – together with the attenuation 
of cachectic manifestations through the decreased production 
of the cachexia-inducing cytokines.98
ATP and creatine
During catabolic conditions, as in illness, energy demands 
often increase and the maintenance of bodyweight becomes 
a balance between such demands and energy supplements. 
It is for this reason that administration of ATP, a directly 
hydrolyzable source of energy, could potentially tip the 
balance towards weight gain and preservation of lean 
body mass. Several clinical data support this observation.99,100 
Using a similar principle, perhaps more directly linked with 
skeletal muscle, creatine administration may result in an 
increase in skeletal muscle phosphocreatine content, which 
may protect the tissue during catabolic conditions. This new 
therapeutic approach merits further attention.
Proteolytic system inhibitors
Enhanced protein degradation in skeletal muscle during 
cachexia involves activation of the ubiquitin/proteasome 
system in muscle. Therefore, inhibitors of this proteolytic 
system such as peptide aldehyde, lactacystin and β-lactone – 
which can effectively block up to 90% of the degradation of 
both normal and short-lived cellular proteins – are poten-
tial drugs for the treatment of muscle wasting.101 However, 
the toxicity of such compounds is fairly high since they are 
not specific inhibitors of the proteolytic system in muscle 
tissue.102 Therefore a substance that can specifically block 
myofibrillar protein degradation in skeletal muscle is still 
awaiting discovery. The discovery of specific muscle ubiquitin 
ligases (Atrogin-1 and MuRF1) is particularly interesting 
since a tissue-specific inhibition of ubiquitin/proteasome 
proteolysis could be achieved if inhibitors of these ligases 
were discovered.103
Myostatin
Myostatin, a transforming growth factor beta (TGF-β) 
superfamily member, has been well characterized as a 
negative regulator of muscle growth and development. 
Myostatin has been implicated in several forms of muscle 
wasting, including the severe cachexia observed as a result 
of conditions such as AIDS and liver cirrhosis. McFarlane 
et al have demonstrated that myostatin induces cachexia 
through an NF-κB-independent mechanism by antagonizing 
hypertrophy signaling through regulation of the AKT-FoxO1 
pathway.104 Anti-myostatin strategies are therefore promising 
and should be considered in future clinical trials involving 
cachectic patients.
CRF2R agonists
The corticotropin-releasing factor 2 receptor (CRF2R) has 
many biological activities including modulation of the stress 
response and has been involved in the prevention of skeletal 
muscle wasting that results from a variety of physiological 
stimuli. Therefore the use of CRF2R agonists has proved 
successful in partially blocking muscle wasting in several 
models of experimental cachexia.105,106 However, a lack of 
clinical data exists.Cancer Management and Research 2010:2 36
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Conclusion: a multifactorial 
approache
From all the data presented, one can speculate that a single 
therapy may not be the best approach in treating cachexia 
and treatment regimens involving different combinations 
are more likely to be successful. Indeed the combination 
of different nutraceuticals with a high energy diet has 
led to beneficial effects in experimental animals.107 An 
interesting phase II study, involving the administration of 
anti-oxidants, pharmaconutritional support, progestagen 
and anti-cyclooxygenase-2 drugs, showed both efficacy and 
safety in the treatment of patients with advanced cancer 
of different sites suffering from cachexia. Based on the 
results of the phase II study, a randomized phase III study 
started in 2005 (and still in progress) includes more than 
300 cachectic cancer patients.108 These data clearly reinforce 
the use of these multi-targeted therapies in the treatment of 
the cachexia–anorexia syndrome in different clinical condi-
tions such as cancer, AIDS and CHF.109
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